Ovarian Cancer

Latest News

Hospital exterior | Image Credit: Spiroview Inc. - stock.adobe.com
Greater NACT Use at High-Volume Centers Linked to Lower Surgical Mortality, Longer Survival in Advanced Ovarian Cancer

August 13th 2025

High-volume cancer centers utilizing neoadjuvant chemotherapy (NACT) significantly reduce surgical mortality and enhance survival rates in patients with advanced ovarian cancer.

Ovarian cancer awareness | Image Credit: SewcreamStudio - stock.adobe.com
Patients With Ovarian Cancer, Higher Social Vulnerability Face Delayed Treatment but Earlier Palliative Care Consultations

August 6th 2025

Ovarian cancer awareness | Image Credit: Queenmoonlite Studio - stock.adobe.com
Underuse of Maintenance Therapies Highlights Need for Improved Care Strategies in Advanced Ovarian Cancer

July 21st 2025

3D ovarian cancer illustration | Image Credit: Lars Neumann - stock.adobe.com
Updated OVARIO Trial Results Reinforce Niraparib Plus Bevacizumab Maintenance for Advanced Ovarian Cancer

July 13th 2025

GLP-1 receptor agonists | Image Credit: K KStock - stock.adobe.com
GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer

July 11th 2025

Advancing Ovarian Cancer Treatment: Insights From Emerging Therapies

Discover how advancements in BRCA, folate receptor alpha, HER2, and CCNE1 testing are shaping ovarian cancer care while addressing barriers in education, access, and tumor diversity.

AJMC Insights logo displayed over a dark blue abstract background with flowing wave-like patterns.
Continuing Medical Education
View All
August 21st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 21st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com
June 30th 2024

Fertility-Sparing Surgery Outcomes Comparable With Radical Surgery in Stage I Epithelial Ovarian Cancer

Brooke McCormick
Researchers found no significant differences in disease-free survival, overall survival, and recurrence rates between fertility-sparing surgery and radical surgery for patients with stage I epithelial ovarian cancer.
Doctor holding animated uterus and ovaries anatomy | Image Credit: Orawan - stock.adobe.com
June 28th 2024

Study: NLR, PLR May Be Early Prognostic Markers for Patients With Ovarian Cancer

Brooke McCormick
High neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are associated with worse progression-free survival and 5-year overall survival in patients with ovarian cancer.
Ovarian cancer | Image credit: Lars Neumann - stock.adobe.com
June 26th 2024

Fears, Concerns for Patients and Loved Ones Intensify Due to Recurrent Ovarian Cancer

Julia Bonavitacola
Supportive care interventions could help address concerns and help patients during the recurrence of ovarian cancer.
Medical team in operating room | Image Credit: Georgii - stock.adobe.com
June 25th 2024

Study Highlights Differences in Cytoreduction's Impact on Survival Among Ovarian Cancer Subtypes

Brooke McCormick
The association between residual tumor volume after primary cytoreduction and survival was less consistent in patients with low-grade serous ovarian carcinoma (LGSOC) compared with other histology types, highlighting variability in surgical outcomes across ovarian cancer subtypes.
"Prognosis" written on blackboard | Image Credit: Yury Zap - stock.adobe.com
June 20th 2024

Surgery Plus Chemotherapy Shows Promise for Stage IV Epithelial Ovarian Cancer

Brooke McCormick
Patients with stage IV epithelial ovarian cancer (OC) treated with surgery and chemotherapy exhibit the best prognosis.
Female patient checking thyroid gland | Image Credit: Jo Panuwat D - stock.adobe.com
June 10th 2024

Hyperthyroidism Potentially Linked to Increased Ovarian Cancer Risk

Brooke McCormick
There may be a causal relaPatients with hyperthyroidism are at increased risk of ovarian cancer (OC), although the link between the conditions is not yet fully understood.
Salad, weights, and measuring tape | Image Credit: freebird7977 - stock.adobe.com
May 28th 2024

Exercise, Diet Interventions Boost Fat-Free Mass, Reduce Fatigue in Patients With OC

Brooke McCormick
Exercise and dietary interventions reduced fatigue and improved both fat-free mass and physical functioning in patients with ovarian cancer (OC), but no significant differences in improvement were found between the intervention and control groups.
Animation of a liver with cancer cell growth | Image Credit: Rasi - stock.adobe.com
May 21st 2024

Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases

Brooke McCormick
Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%.
What We’re Reading: Genetic Markers Predict Weight Loss Response; Talc Baby Powder Linked to Ovarian Cancer; Safeguard for IVF Access Nationwide
May 20th 2024

What We’re Reading: Predicting Weight Loss Response; Talc Baby Powder and Ovarian Cancer; Safeguarding IVF Access

AJMC Staff
Certain genes have been linked to significant weight reduction in obesity treatment; research boosts plaintiffs’ cases against Johnson & Johnson for their talc-based baby powder; proposed legislation aims to address concerns following Alabama Supreme Court ruling on embryos.
Female patient with hands over heart | Image Credit: fizkes - stock.adobe.com
May 17th 2024

Age, Tumor Metastasis, Surgical Treatment Contribute to Cardiovascular Mortality in Patients With Ovarian Cancer

Brooke McCormick
The researchers identified age, tumor metastasis, and surgical treatment as key independent prognostic factors for cardiovascular mortality in patients with ovarian cancer, highlighting the need for individualized treatment and surveillance strategies.
Patient with red eye | Image Credit: Kryuchka Yaroslav - stock.adobe.com
May 13th 2024

Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence

Brooke McCormick
Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Ovarian cancer | Image credit: blueringmedia - stock.adobe.com
May 1st 2024

BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer

Rose McNulty
Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
3D illustration of ovarian cancer | Image Credit: Lars Neumann - stock.adobe.com
April 24th 2024

Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases

Brooke McCormick
This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Patient in hospital bed | Image Credit: Gorodenkoff - stock.adobe.com
April 21st 2024

Black Patients With Ovarian Cancer Had Lower-Quality End-of-Life Care, Study Says

Brooke McCormick
Non-Hispanic Black (NHB) patients with ovarian cancer (OC) receive lower-quality end of life (EOL) care compared to their non-Hispanic White (NHW) counterparts, according to a study.
Chemotherapy | Image Credit: tashatuvango - stock.adobe.com
April 17th 2024

Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US

Brooke McCormick
There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Ovarian cancer illustration | Image credit: Chrystal light - stock.adobe.com
April 12th 2024

Most Patients With Mucinous Ovarian Cancer Don't Need Perioperative GI Endoscopy

Rose McNulty
A new study suggests routine gastrointestinal (GI) endoscopy is not needed for most patients with mucinous ovarian cancer in the perioperative setting due to a lack of statistically significant overall survival benefits.
Ovarian cancer | Image credit: blueringmedia - stock.adobe.com
April 4th 2024

Model Including Diffusion-Weighted MRI More Accurately Predicts Ovarian Cancer Resectability

Rose McNulty
A recent study suggests a modified model incorporating diffusion-weighted MRI can more accurately predict ovarian cancer primary debulking surgery outcomes compared with the standard, widely used Memorial Sloan Kettering Cancer Center risk model.
Patients Treated With Mirvetuximab Soravtansine vs Chemotherapy Report Better HRQOL
March 29th 2024

Patients Treated With Mirvetuximab Soravtansine vs Chemotherapy Report Better HRQOL

Rose McNulty
An abstract presented at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer explored patient-reported health-related quality of life (HRQOL) among patients treated with mirvetuximab soravtansine compared with standard chemotherapy.
FDA approved - Image credit: wladimir1804 - stock.adobe.com
March 22nd 2024

Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer

Rose McNulty
Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Video 6 - "Closing Thoughts on the Current Ovarian Cancer Treatment Landscape"
March 18th 2024

Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.
Video 5 - "Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment"
March 18th 2024

Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

A medical professional examines the pivotal roles of molecular profiling, next-generation sequencing, and germline testing in guiding treatment decisions for ovarian cancer.
Colored Genetic Code DNA Molecule Structure | Image credit: ktsdesign - stock.adobe.com
March 15th 2024

Study Identifies Potential Genomic Markers for Residual Ovarian Cancer Following Resection

Rose McNulty
A recent study found that certain gene variants may be prognostic for residual disease following resection in patients with ovarian cancer.
AI image of microscope looking at ovarian cancer cells | Image credit: Justlight - stock.adobe.com
March 6th 2024

Tumor-Stroma Proportion Predicts Clinical Outcomes in Ovarian Cancer

Rose McNulty
A recent study found that tumor-stroma proportion was a reliable marker of chemoresistance, progression-free survival, and overall survival in high-grade serous ovarian cancer.
Ovarian cancer | Image credit: Crystal light - stock.adobe.com
March 1st 2024

CA-125 Shows Poor Concordance With Radiologic Progression in Ovarian Cancer

Rose McNulty
Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive disease based on RECIST criteria.
Woman consulting with doctor | Image credit: Chinnapong - stock.adobe.com
February 23rd 2024

Study Shows Disparities in Psychosocial Outcomes Among Women With Ovarian Cancer in Rural vs Urban Areas

Rose McNulty
Patients with ovarian cancer living in rural areas reported less improvement in psychological function compared with patients living in urban areas in the year following ovarian cancer diagnosis.
Nutritional Counseling | Image credit: shidlovski - stock.adobe.com
February 14th 2024

Nutritional Intervention May Improve Outcomes but Is Underresearched in Ovarian Cancer

Rose McNulty
A recent review suggests patients diagnosed with ovarian cancer may benefit from nutritional intervention as part of disease management, but research on the topic has been limited and further investigation is warranted.
Female reproductive system concept image - Aliaksandr Marko - stock.adobe.com
February 14th 2024

Review Reinforces Safety, Efficacy of Mirvetuximab Soravtansine in Recurrent FRα-Positive Ovarian Cancer

Rose McNulty
A review and meta-analysis found mirvetuximab soravtansine to have encouraging efficacy and a tolerable safety profile in patients with recurrent ovarian cancer with folate receptor alpha (FRα) expression.
Ovarian cancer illustration - magicmine - stock.adobe.com
February 9th 2024

15-Year Analysis Shows Decrease in Ovarian Cancer Incidence, Incidence-Based Mortality

Rose McNulty
The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with epithelial cancer, especially in advanced stages.
Ovarian cancer | Image credit: blueringmedia - stock.adobe.com
February 2nd 2024

CD137+ Tumor Infiltrating Lymphocytes Correlate With OS in Ovarian Cancer, Study Finds

Rose McNulty
In patients with high-grade ovarian cancer, an increased proportion of CD3+ CD137+ tumor infiltrating lymphocytes (TILs) correlated with favorable overall survival outcomes. However, proportions of CD3+ or CD3+ CD8+ TILs did not show significant associations with OS.
Ovarian Cancer | Image credit: Crystal Light - stock.adobe.com
January 25th 2024

Machine Learning–Based Classifier Accurately Identifies Ovarian Cancer

Rose McNulty
A predictive model utilizing serum metabolic profiles was able to distinguish ovarian cancer from control samples with 93% accuracy, according to a new study.
<1234567>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo